• PMS, GPR30, and Osteoporosis: What the Study Shows

  2026-10-14

  Wu and colleagues combined zebrafish disease modeling, MC3T3-E1 osteoblast research, intracellular exposure analysis, network pharmacology, and antagonist-based signaling tests to examine how PMS may promote osteoblastic activity. The findings support involvement of the GPR30/PI3K/AKT axis, but the evidence remains preclinical and does not establish clinical efficacy or exclusive pathway dependence.

• Haloprogin: What the 1970 Study Showed

  2026-10-13

  A source-grounded overview of Harrison and colleagues’ 1970 evaluation of Haloprogin, covering its comparative antifungal findings, broader in-vitro activity, guinea-pig evidence, and important limits on clinical interpretation.

• WM-8014: Evidence for KAT6A Inhibition

  2026-10-13

  WM-8014 is described by APExBIO as a reversible, competitive inhibitor of MYST-family histone acetyltransferases, with greatest reported biochemical potency toward KAT6A and KAT6B. Supplier-reported studies associate it with cell-cycle arrest and senescence-related responses in mouse fibroblasts and reduced proliferation in a zebrafish liver model. These findings are preclinical and model-specific; they do not establish clinical efficacy, selectivity in every biological context, or use as a therapeutic agent.

• Tacalcitol Monohydrate: Evidence and Boundaries

  2026-10-12

  Tacalcitol monohydrate is a synthetic analog of vitamin D3 with supplier-described activity involving the vitamin D receptor and reported relevance to dermatology, nerve growth factor biology, and colorectal cancer research. The supplied evidence does not directly validate these claims or establish clinical, anticancer, or antithrombotic use. A separate mouse study of berberrubine illustrates why findings from another vitamin-related compound cannot be extrapolated to tacalcitol.

• Azithromycin as a Reported Senolytic: Evidence Review

  2026-10-12

  Ozsvari et al. reported that azithromycin and roxithromycin preferentially reduced senescent human fibroblasts in an in-vitro screening model. The findings support a hypothesis for senolytic activity, but the evidence remains limited by the small number of cell models, the induced form of senescence, assay dependence and the absence of clinical validation.

• LINC01977, Super-Enhancers, and Early LUAD

  2026-10-10

  Zhang et al. identify a super-enhancer-driven regulatory circuit in which LINC01977 reinforces canonical TGF-β/SMAD3 signaling and promotes malignant behavior in early-stage lung adenocarcinoma. The study connects enhancer activity, tumor-associated macrophage signaling, transcriptional coactivator engagement, and clinical outcome, while also defining important boundaries for translation into therapeutic research.

• Uridine, Trisodium Salt: Evidence Beyond PRINT

  2026-10-09

  Uridine, Trisodium Salt is examined through a claim-to-evidence framework that separates nucleoside biochemistry from the findings of the PRINT genome-insertion study. This article clarifies what the research supports, where product data remain descriptive, and how the distinction matters for RNA metabolism and vascular biology interpretation.

• Gastric Cancer Assembloids and Drug Response

  2026-10-09

  The 2025 reference study introduces patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations. Its findings show that stromal context changes gene expression and drug sensitivity, supporting more physiologically relevant studies of resistance and personalized treatment response.

• Matrine, YTHDF1, and Thymoma Stemness

  2026-10-08

  A 2026 study links Matrine exposure with reduced stemness-associated behavior and increased apoptosis in EL-4-B5 thymoma cells, identifying YTHDF1 and Wnt/β-catenin signaling as candidate mediators. The work is an informative in vitro mechanism framework, but the absence of direct m6A measurements, animal studies, and clinical validation limits causal and translational conclusions.

• Deferasirox Fe3+ Chelate and Lysosomal Iron Biology

  2026-10-08

  Deferasirox Fe3+ chelate offers a chemically defined lens for interpreting iron-dependent lysosomal stress. This article connects Exjade-related iron chelation research with Ren et al.’s 2025 findings on TCF25, V-ATPase, ferritinophagy, and lysosome-dependent cell death while clearly separating evidence from hypothesis.

• CD38 CAR Binder Structures and Affinity Tuning

  2026-10-07

  Cheng and colleagues combine structural biology, mutational analysis, enzymatic testing, and CAR-T functional studies to explain how two CD38 binders engage the antigen differently. The findings show that affinity, epitope geometry, catalytic inhibition, and fratricide are linked but separable design variables, offering a mechanistic framework for interpreting CD38-targeted CAR optimization.

• RESTRICT-seq and Epigenetic Dependencies in SCC

  2026-10-07

  A 2025 bioRxiv preprint presents RESTRICT-seq as a framework for time-gated CRISPR screening and applies it to the study of epigenetic dependencies associated with SCC resistance. The work is conceptually important for separating temporal effects from resistance phenotypes, but its interpretation remains provisional because the supplied record contains no gene-level results, quantitative effect sizes, or peer-reviewed validation.

• Mubritinib–HSA Binding Study: Methods and Findings

  2026-10-06

  The 2023 reference study combines fluorescence spectroscopy, biochemical analysis, and molecular docking to characterize how mubritinib interacts with human serum albumin. Its findings support moderate-affinity binding at Sudlow site I, measurable local and structural perturbations, and inhibition of albumin esterase-like activity, while also defining important limits on pharmacokinetic interpretation.

• Nanoparticle Uptake by Human Corneal Cells

  2026-10-06

  Azadi and David examined how nanoparticle size and surface chemistry shape uptake by human corneal epithelial cells in a mucosa-informed in vitro model. Their results connect physicochemical properties with probable endocytic routes, while also showing why pathway assignments and cross-study applications require careful controls and cautious interpretation.

• Quercetin in LPS-Induced Depression: Key Findings

  2026-10-05

  A 2026 pre-proof study reports that quercetin reduced depressive-like behaviors, cognitive deficits, and hippocampal inflammatory signals in an LPS-induced mouse model. Its central contribution is linking these effects to suppression of NLRP3 inflammasome-associated neuroinflammation, while leaving clinical efficacy and broader molecular mechanisms unresolved.

8099 records 2/540 page Previous Next 12345 下5页 Last page